{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-024949","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2026-06-11T20:44:20+00:00","discovered_at":"2026-06-11T20:45:00.514663+00:00","generated_at":"2026-06-11T20:45:05.888656+00:00","sec_items":["1.01","1.02","2.01","3.01","5.01","2.03","3.03","5.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Chiesi completes $27/share acquisition of KalVista; shares cease trading on Nasdaq","bullets":["Tender offer accepted 43,152,532 shares (~77.8% of outstanding) at $27.00 cash per share.","Back-end merger closed June 11, 2026; KalVista now wholly owned by Chiesi Group.","KalVista stock halted June 10 and delisted from Nasdaq Global Market effective June 11.","Chiesi takes ownership of EKTERLY (sebetralstat), oral on-demand HAE treatment approved in US, EU, Japan.","Transaction bonuses aggregate $10.5M for CEO, CMO, CFO; gross-up agreement with CFO for Section 4999 excise tax."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-024949","json":"https://secwatch.observer/filing/0001140361-26-024949.json","markdown":"https://secwatch.observer/filing/0001140361-26-024949.md","text":"https://secwatch.observer/filing/0001140361-26-024949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/ny20075902x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:45:05.888656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06d8fac9f2","claim":"William Fairey resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1293dfe332","claim":"Patrick Treanor resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"17ed3ba45c","claim":"Brian J. G. Pereira, MD resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"247cfc702b","claim":"John Hess was appointed as Sole Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"John Hess, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became the sole director"},{"label":"Role","value":"Sole Director"}],"fact_type":"executive_change"},{"claim_id":"39cf2292d3","claim":"Bethany Sensenig resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9fa3583ecd","claim":"Edward W. Unkart resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b021b93361","claim":"Laurence Reid, PhD resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b58393a9d1","claim":"Benjamin L. Palleiko resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c33176e6b7","claim":"Nancy Stuart resigned as Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cdf1136ef0","claim":"John Hess was appointed as other_named_officer at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"John Hess, President and Secretary of Purchaser, became an officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became an officer"}],"fact_type":"executive_change"},{"claim_id":"0bf708fc8fd9a0fa777d52c1a0e6263653840a79","claim":"KalVista Pharmaceuticals, Inc.: Amended and restated bylaws in full.","evidence_excerpt":"as of the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in full","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"c43be6064587259439060d2d9c1cb1e4b036f212","claim":"KalVista Pharmaceuticals, Inc.: Amended and restated certificate of incorporation in its entirety.","evidence_excerpt":"As of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"a6ec3f2695c675233d75541717483d9312e6ebfe","claim":"KalVista Pharmaceuticals, Inc. underwent a change of control involving Chiesi Farmaceutici S.p.A. for $27.00 per Share in cash (closed 2026-06-11).","evidence_excerpt":"Purchaser commenced a tender offer (the “ Offer ”) to acquire all of the outstanding shares of common stock of the Company, par value $0.001 per share (the “ Shares ”), for $27.00 per Share, net to the seller in cash, without interest and subject to any withholding of taxes (the “ Offer Price ”). The Offer and withdrawal rights expired at one minute","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Chiesi Farmaceutici S.p.A."},{"label":"Consideration","value":"$27.00 per Share in cash"},{"label":"Closing","value":"2026-06-11"}],"fact_type":"ma_transaction"},{"claim_id":"77171589b8750e763f73a4cae68991529abeff87","claim":"KalVista Pharmaceuticals, Inc. terminated Company 2015 Incentive Plan with KalVista Pharmaceuticals, Inc. valued at Terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company (effective 2026-06-11).","evidence_excerpt":"In connection with the consummation of the Offer and the Merger and effective as of, and contingent upon, the Effective Time, the Company terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company 2021 Equity Inducement Plan.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"KalVista Pharmaceuticals, Inc."},{"label":"Value","value":"Terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company"},{"label":"Effective","value":"2026-06-11"}],"fact_type":"material_agreement"},{"claim_id":"c22e585ea114f59fab31adcb6b8e3f5805f5e9d0","claim":"KalVista Pharmaceuticals, Inc. terminated Company 2017 Employee Stock Purchase Plan with KalVista Pharmaceuticals, Inc. valued at Terminated the Company 2017 Employee Stock Purchase Plan (effective 2026-06-11).","evidence_excerpt":"In addition, and also effective immediately prior to, and contingent upon, the Effective Time, the Company terminated the Company 2017 Employee Stock Purchase Plan.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"KalVista Pharmaceuticals, Inc."},{"label":"Value","value":"Terminated the Company 2017 Employee Stock Purchase Plan"},{"label":"Effective","value":"2026-06-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}